UnitedHealth to Divest Home Health & Hospice Assets to Resolve antitrust Concerns
Table of Contents
UnitedHealth Group will divest certain home health and hospice locations as part of a settlement with the U.S. Department of Justice (DOJ) to address antitrust concerns stemming from its acquisition of LHC Group inc. (LHC). The DOJ alleged that UnitedHealth falsely certified its compliance with document requests during the examination of the LHC acquisition. This resolution aims to preserve competition in the home health and hospice services market.
Background: The UnitedHealth-LHC Acquisition and DOJ Concerns
In 2023, UnitedHealth, a diversified healthcare company encompassing insurance, healthcare provision, pharmacy benefits, and software services, acquired LHC Group for $5.7 billion. LHC Group was a significant competitor to Amedisys, another major provider of home health and hospice care.
The DOJ initiated an investigation into the acquisition, concerned that it would reduce competition in several local markets. The DOJ’s concerns were compounded by allegations that UnitedHealth and its field leadership provided false certifications regarding their responses to the DOJ’s requests for documents. Specifically, the DOJ claims the company falsely stated it had truthfully, correctly, and completely responded to data requests.
The proposed Settlement and Divestitures
To resolve these concerns, UnitedHealth has agreed to divest home health and hospice locations in several markets. The specific locations are detailed in a map included with the DOJ’s announcement (the map itself is not included here, but is referenced in the original text). the divestiture is intended to restore competition lost due to the acquisition.
The proposed settlement is subject to court approval and public comment. As required by the Tunney Act, the proposed settlement and a competitive impact statement will be published in the Federal Register. Interested parties have 60 days from the date of publication to submit written comments to:
Jill Maguire, Acting Chief
Healthcare and Consumer Products Section
Antitrust Division, U.S.Department of Justice
450 Fifth Street NW, Suite 4100
Washington, DC 20530
Following the public comment period, the U.S. District Court for the District of Maryland will determine whether the final judgment is in the public interest.
Key Players
UnitedHealth Group: A vertically integrated healthcare company headquartered in Eden Prairie, Minnesota. (https://www.unitedhealthgroup.com/)
Amedisys: A home health and hospice services provider headquartered in Baton Rouge, Louisiana. (https://www.amedisys.com/)
LHC Group Inc.: A home health and hospice services provider acquired by UnitedHealth in 2023.
U.S. Department of Justice (DOJ): The federal agency responsible for enforcing antitrust laws. (https://www.justice.gov/)
Key Takeaways
UnitedHealth is divesting home health and hospice assets to resolve DOJ antitrust concerns related to its acquisition of LHC Group.
The DOJ alleged false certifications regarding document production during the investigation.
The settlement aims to restore competition in local markets for home health and hospice services.
The public has an opportunity to comment on the proposed settlement.
Looking Ahead
This settlement underscores the DOJ’s commitment to enforcing antitrust laws in the healthcare industry. The outcome of this case, and the public comments received, will likely influence future healthcare mergers and acquisitions, particularly those involving large, vertically integrated companies like UnitedHealth. The DOJ’s scrutiny of document production and certifications also serves as a warning to companies involved in antitrust investigations to ensure complete and accurate compliance.